Apr 26, 2023 / 04:00PM GMT
Brad Canino - Stifel Financial Corp. - Analyst
Thanks, everyone, for continuing to join us on our inaugural Stifel Target Oncology Days. How many have as Brad Canino, senior analyst here at Stifel, and I'm delighted to be joined by Tim Clackson, the CEO of Theseus, to sit down with me for a about 25-minute fireside chat. So thank you so much, Tim, for joining us.
Tim Clackson - Theseus Pharmaceuticals, Inc. - President & CEO
Thanks, Brad, for the opportunity.
Questions and Answers:
Brad Canino - Stifel Financial Corp. - AnalystCool. Now I think we'll open with a company question but somewhat of a specific question, because I'd love you to just talk about your PRA tool that you use, define it; and why it's important for mutant protein targets, particularly for the drugs in targeted cancers in your pipeline?
Tim Clackson - Theseus Pharmaceuticals, Inc. - President & CEO
Of course. Happy to do that. So PRA stand so the Predictive Resistance Assay. Why are we